造血干细胞体外培养临床应用的研究  

The Responses of Leukemia Cells to Interleukin 2 in Vitro

作　　者：羊裔明[1] 刘明漪[1] 吴谨绪[1] 邓长安[1] 徐功敕[1] 

机构地区：[1]华西医科大学附属第一医院

出　　处：《华西医科大学学报》1997年第2期188-192,共5页Journal of West China University of Medical Sciences

摘　　要：造血干细胞体外培养临床应用的研究成果完成单位华西医科大学附属第一医院主研人员羊裔明刘明漪吴谨绪邓长安徐功敕主持鉴定单位四川省卫生厅鉴定时间１９９６年６月获奖情况获１９９６年度成都市科技进步三等奖成果简介该成果用粒单祖细胞、红系祖细胞体外培养及患者血清...We conducted a study on the utility and safety of rhIL 2 immunotherapy for leukemia.The responses of leukemic cells expressing interleukin 2 receptor(IL 2R) gene obtained from 7 leukemic cell lines,6 cases of acute lymphoblastic leukemia (ALL) and 8 cases of acute myeloid leukemia (AML) were measured by 3H thymidine incorproation.The results showed that the responses of these cells were heterogeneous.The cells expressing IL 2Rα and IL Rβ mRNAs simultanesously from NKL 1,2 cases of ALL and 1 cases of AML(M5) responded to rhIL 2 proliferatively;the cells from 3 leukemic cell lines,2 cases of ALL and 2 cases of AML were inhibited by rhIL 2;the leukemic cells from the remaining 3 leukemic cell lines and 7 cases of leukemia did not respond to rhIL 2.The study demonstrates that the responses of leukemic cells expressing IL 2 receptors to rhIL 2 are heterogeneous.The patterns of the responses are proliferative,being inhibited to rhIL 2,or irresponsive.So rhIL 2 immunotherapy is suitable for the patients whose leukemic cells were inhibited by or did not respond to rhIL 2 in vitro,but this immunotherapy is not suitable for the patients whose leukemic cells responded proliferatively to rhIL 2 in vitro.

关 键 词：白血病细胞 白细胞介素-2 IL-2R 

分 类 号：R733.7[医药卫生—肿瘤]